CEO
Virion Therapeutics
Virion Therapeutics is a clinical-stage biopharmaceutical company developing T cell-based immunotherapies that utilize genetically encoded checkpoint modifiers to enhance CD8+ T cell responses against virally-associated cancers and chronic infectious diseases. Their approach aims to improve clinical outcomes and survival rates in patients, with ongoing human studies for their lead program targeting chronic HBV.
- Biotechnology
Updated 7 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Current treatments for virally-associated cancers and chronic infectious diseases often fail to elicit a sufficient T cell response, leading to poor clinical outcomes and reduced survival rates. Existing immunotherapies may not adequately stimulate and broaden the CD8+ T cell response needed to effectively target and eliminate infected or cancerous cells.
Solution
Virion Therapeutics is developing T cell-based immunotherapies that utilize genetically encoded checkpoint modifiers (CPM) to enhance and broaden CD8+ T cell responses against virally-associated cancers and chronic infectious diseases. Their VIACT™ platform combines CPMs with intelligently selected and optimized target antigens, inserted into heterologous chimpanzee adenoviral vectors. By genetically encoding checkpoint modifiers, Virion aims to optimize CD8+ T cell responses, leading to improved clinical outcomes and survival. The company's iterative scientific approach is designed to produce adaptable and accessible disease-specific CD8+ T cell-based immunotherapies.
Target Audience
The primary target audience includes patients with virally-associated cancers and chronic infectious diseases, as well as clinicians and researchers seeking novel immunotherapeutic approaches.
Features
- Genetically encoded checkpoint modifiers (CPM) to enhance CD8+ T cell responses
- VIACT™ platform combining CPMs with optimized target antigens
- Heterologous chimpanzee adenoviral vectors for targeted delivery
- Disease-specific CD8+ T cell-based immunotherapies
- First-in-human studies for lead VRON-0200 HBV program